Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT04880876
PHASE3

A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Sponsor: AbbVie

View on ClinicalTrials.gov

Summary

This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.

Official title: A Phase 3, Long-term Safety Study of Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Key Details

Gender

All

Age Range

6 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

124

Start Date

2021-08-13

Completion Date

2032-12

Last Updated

2025-07-17

Healthy Volunteers

No

Interventions

DRUG

25mg Eluxadoline

Oral Tablets

DRUG

100mg Eluxadoline

Oral Tablets

Locations (6)

Kindred Medical Institute, LLC /ID# 227595

Corona, California, United States

Valencia Medical & Research Center /ID# 246221

Miami, Florida, United States

Florida Research Center, Inc. /ID# 227597

Miami, Florida, United States

Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 227600

Stockbridge, Georgia, United States

IPS Research Company /ID# 227594

Oklahoma City, Oklahoma, United States

Preferred Primary Care Physicians, Inc. /ID# 227596

Pittsburgh, Pennsylvania, United States